Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4283151 | 0.85 | HRH4 (0.34) | HRH4HRH3POLBL3MBTL1 | |
| SCHEMBL4283869 | 0.83 | POLB (0.44) | ALOX5HRH4HRH3POLB | |
| SCHEMBL4295181 | 0.81 | DPP4 (0.33) | GPR88 | |
| Hydrochloric Acid SCHEMBL4291345 | 0.80 | GPR88 (0.36) | GPR88ALOX5DGAT1SLC6A2SLC6A4 | |
| SCHEMBL4292395 | 0.79 | ALDH1A1 (0.47) | GPR88GLAPOLB | |
| SCHEMBL4294620 | 0.77 | CYP19A1 (0.36) | GPR88HRH4HRH3 | |
| SCHEMBL4285493 | 0.72 | LMNA (0.36) | L3MBTL1 | |
| SCHEMBL4289928 | 0.72 | GAA (0.34) | NPC1 | |
| SCHEMBL4286285 | 0.71 | L3MBTL1 (0.39) | NPC1L3MBTL1 | |
| SCHEMBL4284114 | 0.70 | MCHR1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | GPR88 2034/4885ALOX5 1982/4885DGAT1 4697/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | GPR88 2034/4885ALOX5 1982/4885DGAT1 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.